AMT-253 ADC / Multitude Therap - LARVOL DELTA

AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Solid Tumor

A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma (Clin Cancer Res) - "AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature-targeting by a mouse MUC18-specific antibody-T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts."

Preclinical • Melanoma